Records containing: Melanoma Stage IV
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2025-08-24Phase 1 Study to Evaluate the Safety and Efficacy of TILs Transduced With IL-7 (ADP-TILIL7) in Patients With Locally Advanced or Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2025-07-30Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
-
CLINICAL_TRIALS study record update · 2025-07-03MITRIC: Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clincal Responders
-
CLINICAL_TRIALS study record update · 2025-05-18A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies
-
CLINICAL_TRIALS study record update · 2025-03-12Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2025-03-10Conversion of Unresponsiveness to Immunotherapy by Fecal Microbiota Transplantation in Patients With Metastatic Melanoma: a Randomized Phase Ib/IIa Trial
-
CLINICAL_TRIALS study record update · 2025-02-28Safe Stop IPI-NIVO Trial: Early Discontinuation of Nivolumab Upon Achieving a (confirmed) Complete or Partial Response in Patients with Irresectable Stage III or Metastatic Melanoma Treated with First-line Ipilimumab-nivolumab
-
CLINICAL_TRIALS study record update · 2025-02-27A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2025-01-17Monocentric Study on the Clinical and Ultrasound Incidence of Rheumathologic Immune Related Adverse Events in Patients Affected by Stage IIB, IIC, III and IV Melanoma Under Therapy With Immune-checkpoint Inhibitors
-
CLINICAL_TRIALS study record update · 2024-12-09A Phase II Study of Combination Treatment with TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients with Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma
-
CLINICAL_TRIALS study record update · 2024-11-27Versatile Ampification Method for Single-Molecule Detection in Liquid Biopsy
-
CLINICAL_TRIALS study record update · 2024-10-26A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination with Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients with Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and with Presence of Injectable Metastases
-
CLINICAL_TRIALS study record update · 2024-08-15Phase 1 Clinical Trial to Determine the Safety of TRIMELVax for Stage IIIC and IV Melanoma Patients in Progression to Immunotherapy Treatment (Checkpoint Inhibitors)
-
CLINICAL_TRIALS study record update · 2024-02-21A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence
-
CLINICAL_TRIALS study record update · 2024-01-26Surgery of Melanoma Metastases After Systemic Therapy - the SUMMIST Trial
-
CLINICAL_TRIALS study record update · 2023-11-07A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2023-10-24A Phase-2 Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma - Definition of Two Additional Stratified Patient Cohorts of Regorafenib Plus BRAF-/MEK-inhibitors in Pretreated BRAF V600-mutant Melanoma Patients
-
CLINICAL_TRIALS study record update · 2023-04-21A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
-
CLINICAL_TRIALS study record update · 2022-06-15prospectIve Non-interventional Study of Clinical Outcomes And Biomarkers in Patients With Stage 0-IV mElanoma in reaL clinicaL prActice
-
CLINICAL_TRIALS study record update · 2022-06-01Prospective Evaluation of Clinical Outcomes in Patients With Resectable or Metastatic BRAF+ Melanoma Treated With Dabrafenib and Trametinib in Real Practice
-
CLINICAL_TRIALS study record update · 2022-02-28Appropriate Dosing to Optimise Personalised Cancer Treatments
-
CLINICAL_TRIALS study record update · 2021-10-07Safety and Efficacy Study of Oncolytic Virus（Intratumoral Injection）in Combination With HX-008（Intravenous Injection）and Axitinib in Melanoma Patients With Liver Metastasis Who Lack or Become Refractory to Standard Treatment
-
CLINICAL_TRIALS study record update · 2021-10-05Safety and Efficacy Study of Oncolytic Virus（Intratumoral Injection）in Combination With HX-008（Intravenous Injection）and Radiotherapy for Liver Metastasis in Melanoma Patients With Liver Metastasis Who Lack or Become Refractory to Standard Treatment
-
CLINICAL_TRIALS study record update · 2021-08-16A Phase Ib Trial to Evaluate the Safety and Efficacy of Fecal Microbial Transplantation (FMT) in Combination With Nivolumab in Subjects With Metastatic or Inoperable Melanoma, Microsatellite Instability-high (MSI-H) or Mismatch-repair Deficient (dMMR) Cancer, or Non-Small Cell Lung Cancer (NSCLC)
-
CLINICAL_TRIALS study record update · 2021-05-14Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells in Patients With Advanced or Metastatic Tumors.